Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single-Center, Randomized, Parallel-Group, Single-Dose Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

Next Previous
Trial Profile

An Open-Label, Single-Center, Randomized, Parallel-Group, Single-Dose Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Ankylosing spondylitis; Axial spondyloarthritis; Hidradenitis suppurativa; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors UCB Biopharma

Most Recent Events

  • 12 Aug 2021 Status changed from suspended to discontinued due to difficulties executing the study under the COVID-19 pandemic. .
  • 20 May 2021 Planned End Date changed from 1 Oct 2021 to 1 Dec 2022.
  • 20 May 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top